These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: stability and immunoefficiency studies. Barhate G; Gautam M; Gairola S; Jadhav S; Pokharkar V Int J Pharm; 2013 Jan; 441(1-2):636-42. PubMed ID: 23117021 [TBL] [Abstract][Full Text] [Related]
6. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. van der Lubben IM; Kersten G; Fretz MM; Beuvery C; Coos Verhoef J; Junginger HE Vaccine; 2003 Mar; 21(13-14):1400-8. PubMed ID: 12615436 [TBL] [Abstract][Full Text] [Related]
7. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Tafaghodi M; Sajadi Tabassi SA; Jaafari MR Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972 [TBL] [Abstract][Full Text] [Related]
8. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D,L-lactic-co-glycolic acid) versus chitosan microspheres. Jaganathan KS; Rao YU; Singh P; Prabakaran D; Gupta S; Jain A; Vyas SP Int J Pharm; 2005 Apr; 294(1-2):23-32. PubMed ID: 15814228 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Singh M; Li XM; Wang H; McGee JP; Zamb T; Koff W; Wang CY; O'Hagan DT Infect Immun; 1997 May; 65(5):1716-21. PubMed ID: 9125552 [TBL] [Abstract][Full Text] [Related]
10. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Vila A; Sánchez A; Janes K; Behrens I; Kissel T; Vila Jato JL; Alonso MJ Eur J Pharm Biopharm; 2004 Jan; 57(1):123-31. PubMed ID: 14729088 [TBL] [Abstract][Full Text] [Related]
11. Oral vaccine models: multiple delivery systems employing tetanus toxoid. Jackson RJ; Staats HF; Xu-Amano J; Takahashi I; Kiyono H; Hudson ME; Gilley RM; Chatfield SN; McGhee JR Ann N Y Acad Sci; 1994 Aug; 730():217-34. PubMed ID: 8080173 [TBL] [Abstract][Full Text] [Related]
12. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762 [TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of chitosan microspheres for tetanus, diphtheria and divalent vaccines: a comparative study of subcutaneous and intranasal administration in mice. Hashem FM; Fahmy SA; El-Sayed AM; Al-Sawahli MM Pharm Dev Technol; 2013; 18(5):1175-85. PubMed ID: 21985525 [TBL] [Abstract][Full Text] [Related]
14. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit. Isaka M; Yasuda Y; Kozuka S; Miura Y; Taniguchi T; Matano K; Goto N; Tochikubo K Vaccine; 1998 Oct; 16(17):1620-6. PubMed ID: 9713937 [TBL] [Abstract][Full Text] [Related]
15. Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. Jain S; Harde H; Indulkar A; Agrawal AK Nanomedicine; 2014 Feb; 10(2):431-40. PubMed ID: 24036099 [TBL] [Abstract][Full Text] [Related]
16. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Jung T; Kamm W; Breitenbach A; Hungerer KD; Hundt E; Kissel T Pharm Res; 2001 Mar; 18(3):352-60. PubMed ID: 11442276 [TBL] [Abstract][Full Text] [Related]
17. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Mann JF; Scales HE; Shakir E; Alexander J; Carter KC; Mullen AB; Ferro VA Methods; 2006 Feb; 38(2):90-5. PubMed ID: 16414269 [TBL] [Abstract][Full Text] [Related]
18. Mucosal and systemic immune responses following mucosal immunisation of tetanus toxoid entrapped in lipid nanoparticles prepared by microwave reactor. Gebril A; Obeid MA; Bennett EM; Pujol A; Chovel ML; Mahy T; Acevedo R; Ferro VA Eur J Pharm Biopharm; 2022 Feb; 171():11-18. PubMed ID: 34990784 [TBL] [Abstract][Full Text] [Related]
19. Dextran microspheres could enhance immune responses against PLGA nanospheres encapsulated with tetanus toxoid and Quillaja saponins after nasal immunization in rabbit. Mohaghegh M; Tafaghodi M Pharm Dev Technol; 2011 Feb; 16(1):36-43. PubMed ID: 20082579 [TBL] [Abstract][Full Text] [Related]
20. Induction of high antitoxin titers against tetanus toxoid in rabbits by intranasal immunization with dextran microspheres. Sajadi Tabassi SA; Tafaghodi M; Jaafari MR Int J Pharm; 2008 Aug; 360(1-2):12-7. PubMed ID: 18538516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]